Endocrine Society of Australia position statement on male hypogonadism (Part 2): Treatment and therapeutic considerations

Bu B. Yeap, Mathis Grossmann, Robert I. McLachlan, David J. Handelsman, Gary A. Wittert, Ann J. Conway, Bronwyn G A Stuckey, Douglas W. Lording, Carolyn A. Allan, Jeffrey D. Zajac, Henry G. Burger

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research. Main recommendations: Key points and recommendations are: ● Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment. Additional studies are needed to clarify whether testosterone therapy influences cardiovascular risk. ● Testosterone is the native hormone that should be replaced in men being treated for pathological hypogonadism. Convenient and cost-effective treatment modalities include depot intramuscular injection and transdermal administration (gel, cream or liquid formulations). ● Monitoring of testosterone therapy is recommended for efficacy and safety, focusing on ameliorating symptoms, restoring virilisation, avoiding polycythaemia and maintaining or improving bone mineral density. ● Treatment aims to relieve an individual’s symptoms and signs of androgen deficiency by administering standard doses and maintaining circulating testosterone levels within the reference interval for eugonadal men. ● Evaluation for cardiovascular disease and prostate cancer risks should be undertaken as appropriate for eugonadal men of similar age. Nevertheless, when there is a reasonable possibility of substantive pre-existing prostate disease, digital rectal examination and prostate-specific antigen testing should be performed before commencing testosterone treatment. Changes in management as result of the position statement: Treatment aims to relieve symptoms and signs of androgen deficiency, using convenient and effective formulations of testosterone. Therapy should be monitored for efficacy and safety.

Original languageEnglish
Pages (from-to)228-231
Number of pages4
JournalMedical Journal of Australia
Volume205
Issue number5
DOIs
Publication statusPublished - 5 Sep 2016
Externally publishedYes

Cite this

Yeap, Bu B. ; Grossmann, Mathis ; McLachlan, Robert I. ; Handelsman, David J. ; Wittert, Gary A. ; Conway, Ann J. ; Stuckey, Bronwyn G A ; Lording, Douglas W. ; Allan, Carolyn A. ; Zajac, Jeffrey D. ; Burger, Henry G. / Endocrine Society of Australia position statement on male hypogonadism (Part 2) : Treatment and therapeutic considerations. In: Medical Journal of Australia. 2016 ; Vol. 205, No. 5. pp. 228-231.
@article{9dffb9faf3e540f585838f5454364938,
title = "Endocrine Society of Australia position statement on male hypogonadism (Part 2): Treatment and therapeutic considerations",
abstract = "Introduction: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research. Main recommendations: Key points and recommendations are: ● Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment. Additional studies are needed to clarify whether testosterone therapy influences cardiovascular risk. ● Testosterone is the native hormone that should be replaced in men being treated for pathological hypogonadism. Convenient and cost-effective treatment modalities include depot intramuscular injection and transdermal administration (gel, cream or liquid formulations). ● Monitoring of testosterone therapy is recommended for efficacy and safety, focusing on ameliorating symptoms, restoring virilisation, avoiding polycythaemia and maintaining or improving bone mineral density. ● Treatment aims to relieve an individual’s symptoms and signs of androgen deficiency by administering standard doses and maintaining circulating testosterone levels within the reference interval for eugonadal men. ● Evaluation for cardiovascular disease and prostate cancer risks should be undertaken as appropriate for eugonadal men of similar age. Nevertheless, when there is a reasonable possibility of substantive pre-existing prostate disease, digital rectal examination and prostate-specific antigen testing should be performed before commencing testosterone treatment. Changes in management as result of the position statement: Treatment aims to relieve symptoms and signs of androgen deficiency, using convenient and effective formulations of testosterone. Therapy should be monitored for efficacy and safety.",
author = "Yeap, {Bu B.} and Mathis Grossmann and McLachlan, {Robert I.} and Handelsman, {David J.} and Wittert, {Gary A.} and Conway, {Ann J.} and Stuckey, {Bronwyn G A} and Lording, {Douglas W.} and Allan, {Carolyn A.} and Zajac, {Jeffrey D.} and Burger, {Henry G.}",
year = "2016",
month = "9",
day = "5",
doi = "10.5694/mja16.00448",
language = "English",
volume = "205",
pages = "228--231",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",
number = "5",

}

Endocrine Society of Australia position statement on male hypogonadism (Part 2) : Treatment and therapeutic considerations. / Yeap, Bu B.; Grossmann, Mathis; McLachlan, Robert I.; Handelsman, David J.; Wittert, Gary A.; Conway, Ann J.; Stuckey, Bronwyn G A; Lording, Douglas W.; Allan, Carolyn A.; Zajac, Jeffrey D.; Burger, Henry G.

In: Medical Journal of Australia, Vol. 205, No. 5, 05.09.2016, p. 228-231.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Endocrine Society of Australia position statement on male hypogonadism (Part 2)

T2 - Treatment and therapeutic considerations

AU - Yeap, Bu B.

AU - Grossmann, Mathis

AU - McLachlan, Robert I.

AU - Handelsman, David J.

AU - Wittert, Gary A.

AU - Conway, Ann J.

AU - Stuckey, Bronwyn G A

AU - Lording, Douglas W.

AU - Allan, Carolyn A.

AU - Zajac, Jeffrey D.

AU - Burger, Henry G.

PY - 2016/9/5

Y1 - 2016/9/5

N2 - Introduction: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research. Main recommendations: Key points and recommendations are: ● Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment. Additional studies are needed to clarify whether testosterone therapy influences cardiovascular risk. ● Testosterone is the native hormone that should be replaced in men being treated for pathological hypogonadism. Convenient and cost-effective treatment modalities include depot intramuscular injection and transdermal administration (gel, cream or liquid formulations). ● Monitoring of testosterone therapy is recommended for efficacy and safety, focusing on ameliorating symptoms, restoring virilisation, avoiding polycythaemia and maintaining or improving bone mineral density. ● Treatment aims to relieve an individual’s symptoms and signs of androgen deficiency by administering standard doses and maintaining circulating testosterone levels within the reference interval for eugonadal men. ● Evaluation for cardiovascular disease and prostate cancer risks should be undertaken as appropriate for eugonadal men of similar age. Nevertheless, when there is a reasonable possibility of substantive pre-existing prostate disease, digital rectal examination and prostate-specific antigen testing should be performed before commencing testosterone treatment. Changes in management as result of the position statement: Treatment aims to relieve symptoms and signs of androgen deficiency, using convenient and effective formulations of testosterone. Therapy should be monitored for efficacy and safety.

AB - Introduction: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research. Main recommendations: Key points and recommendations are: ● Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment. Additional studies are needed to clarify whether testosterone therapy influences cardiovascular risk. ● Testosterone is the native hormone that should be replaced in men being treated for pathological hypogonadism. Convenient and cost-effective treatment modalities include depot intramuscular injection and transdermal administration (gel, cream or liquid formulations). ● Monitoring of testosterone therapy is recommended for efficacy and safety, focusing on ameliorating symptoms, restoring virilisation, avoiding polycythaemia and maintaining or improving bone mineral density. ● Treatment aims to relieve an individual’s symptoms and signs of androgen deficiency by administering standard doses and maintaining circulating testosterone levels within the reference interval for eugonadal men. ● Evaluation for cardiovascular disease and prostate cancer risks should be undertaken as appropriate for eugonadal men of similar age. Nevertheless, when there is a reasonable possibility of substantive pre-existing prostate disease, digital rectal examination and prostate-specific antigen testing should be performed before commencing testosterone treatment. Changes in management as result of the position statement: Treatment aims to relieve symptoms and signs of androgen deficiency, using convenient and effective formulations of testosterone. Therapy should be monitored for efficacy and safety.

UR - http://www.scopus.com/inward/record.url?scp=84987711849&partnerID=8YFLogxK

U2 - 10.5694/mja16.00448

DO - 10.5694/mja16.00448

M3 - Article

VL - 205

SP - 228

EP - 231

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 5

ER -